Drug Resistance in Colorectal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 1 May 2024 | Viewed by 158
Special Issue Editor
Special Issue Information
Dear Colleagues,
Colorectal cancer is the third most common cancer worldwide, Despite the development of effective small molecules targeting oncogenic drivers, many patients relapse as treatment proceeds. Indeed, the failure of chemotherapy leaves resistant cancer cells to survive, eventually leading to the death of patients. Drug resistance remains a pressing concern, impacting the effectiveness of therapeutic interventions in colorectal cancer patients. Insights and cutting-edge research in this area are pivotal to advancing our understanding and improving patient outcomes. Therefore, we are actively seeking contributions that delve into the mechanisms, novel approaches, clinical implications, and therapeutic strategies related to drug resistance in colorectal cancers.
This Special Issue will highlight the current state of the art in the diverse molecular mechanisms of drug resistance along with novel targets and prospects for improving treatment outcomes for patients with resistant and refractory disease. The articles curated for this issue will put forth a current understanding of the molecular mechanisms underlying drug resistance acquired by tumor cells in vitro and in vivo and will provide an landscape view of novel therapeutic strategies. These emerging therapeutic strategies can encompass the modulation of the microenvironment, the establishment of diagnostic biomarkers, combination therapies, immune modulation, and the growing potential of spatial transcriptomics in drug development.
Dr. Rebecca Boohaker
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- therapeutics
- chemoresistance
- precision medicine
- drug resistance
